WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials

Linda Stein-Gold; Leon H Kircik; Zoe Diane Draelos; Philip Werschler; Janet DuBois; Edward Lain; Leslie Baumann; David J Goldberg; Joely Kaufman; Emil A Tanghetti; Nancy Alvandi; Emily Weng; David R Berk; Gurpreet Ahluwalia

doi:10.1016/j.jaad.2018.01.028

WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials

J Am Acad Dermatol. 2018 Jan 31:S0190-9622(18)30147-6. doi: 10.1016/j.jaad.2018.01.028. Online ahead of print.

Authors

Affiliations

¹ Henry Ford Health System, West Bloomfield, Michigan.
² Icahn School of Medicine at Mount Sinai, New York, New York.
³ Dermatology Consulting Services, High Point, North Carolina.
⁴ Premier Clinical Research, Spokane, Washington.
⁵ DermResearch, Inc, Austin, Texas.
⁶ Austin Institute for Clinical Research, Austin, Texas.
⁷ Baumann Cosmetic and Research Institute, Inc, Miami, Florida.
⁸ Skin Laser and Surgery Specialists of NY and NJ, New York, New York.
⁹ Skin Associates and Skin Research Institute, Coral Gablesi, Florida.
¹⁰ Center for Dermatology and Laser Surgery, Sacramento, California.
¹¹ Allergan plc, Irvine, California.

PMID: 29409915
DOI: 10.1016/j.jaad.2018.01.028

Abstract

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

Publication types

Retraction of Publication
Retracted Publication